A Study Comparing CMF (Cyclophosphamide, Methotrexate, 5-fluorouracil) and MMM (Mitozantrone, Methotrexate, Mitomycin-C) Chemotherapy in Patients with Metastatic Breast Cancer

Completed

• Conditions: Breast cancer; Cancer; Breast

• Registration Number: ISRCTN92834934
• Lead Sponsor: Cancer Research UK (CRUK) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2002-08-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

1. Histologically proven breast cancer, metastatic or incurable locally recurrent disease
2. No other malignancy except adequately treated in situ carcinoma of cervix or non melanomatous skin cancer
3. Previous adjuvant chemotherapy or neo-adjuvant chemotherapy is acceptable, unless the disease free interval is <2 years following adjuvant CMF chemotherapy
4. Previous chemotherapy for metastatic disease is acceptable
5. Patients must be willing to complete quality of life questionnaire and be interviewed by a senior nurse
6. Normal liver function
7. Patients must be considered fit enough to receive either standard CMF or MMM chemotherapy

Exclusion Criteria

1. Patients are not eligible if they are eligible for a first line phase II study. Patients may become eligible at the time of progression
2. Patient are not eligible if they present with immediately life threatening disease for whom the physician considers an anthracycline based combination preferable

Study & Design

• Study Type: Interventional
• Study Design: Not specified